Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Semin Oncol Retrieve available abstracts of 12 articles: HTML format Text format

Single Articles

October 2018
1. MARUR S, Singh H, Mishra-Kalyani P, Larkins E, et al
   FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
   Semin Oncol. 2018 Oct 31. pii: S0093-7754(18)30157.
   PubMed     Text format     Abstract available
   
   
   
2. KING-KALLIMANIS BL, Kanapuru B, Blumenthal GM, Theoret MR, et al
   Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
   Semin Oncol. 2018 Oct 25. pii: S0093-7754(18)30127.
   PubMed     Text format     Abstract available
   
   
   
3. LAKING G, Evans J, Metcalfe S, Strother RM, et al
   Response to Cameron et al "Mind the graph" Semin Oncol. 2018.
   Semin Oncol. 2018;45.
   PubMed     Text format    
   
   
   July 2018
4. SHINDE A, Li R, Kim J, Salgia R, et al
   Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
   Semin Oncol. 2018 Jul 1. pii: S0093-7754(18)30008.
   PubMed     Text format     Abstract available
   
   
   June 2018
5. PILOTTO S, Carbognin L, Rossi A, Tortora G, et al
   Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
   Semin Oncol. 2018;45:176-180.
   PubMed     Text format     Abstract available
   
   
   January 2018
6. SANCHEZ L, Muchene L, Lorenzo-Luaces P, Viada C, et al
   Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer.
   Semin Oncol. 2018;45.
   PubMed     Text format     Abstract available
   
   
   
7. SAAVEDRA D, Neninger E, Rodriguez C, Viada C, et al
   CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
   Semin Oncol. 2018;45.
   PubMed     Text format     Abstract available
   
   
   June 2017
8. TABCHI S, Kassouf E, Rassy EE, Kourie HR, et al
   Management of stage III non-small cell lung cancer.
   Semin Oncol. 2017;44:163-177.
   PubMed     Text format     Abstract available
   
   
   April 2017
9. PRASAD V, Kaestner V
   Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
   Semin Oncol. 2017;44:132-135.
   PubMed     Text format     Abstract available
   
   
   February 2017
10. PINSKY PF
    Commentary on "Screening for lung cancer" by Sateia et al.
    Semin Oncol. 2017;44:83-84.
    PubMed     Text format    
    
    
    
11. SATEIA HF, Choi Y, Stewart RW, Peairs KS, et al
    Screening for lung cancer.
    Semin Oncol. 2017;44:74-82.
    PubMed     Text format     Abstract available
    
    
    
12. KAZANDJIAN D, Keegan P, Suzman DL, Pazdur R, et al
    Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.
    Semin Oncol. 2017;44:3-7.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: